hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06352242, orgStudyIdInfo id: RECHMPL24-0076 UF 9572, briefTitle: Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?, acronym: CARTROG, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2026-04-08, completionDateStruct date: 2026-04-08, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, descriptionModule briefSummary: CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL., conditionsModule conditions: Diffuse Large B Cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 85, type: ESTIMATED, armsInterventionsModule interventions name: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients, interventions name: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers, outcomesModule primaryOutcomes measure: Identification of a phenotypic "signature" of trogocytosis predictive of failure to achieve a complete metabolic response for patients with diffuse large B-cell lymphoma., secondaryOutcomes measure: Identification of a phenotypic "signature" of trogocytosis predictive of the occurrence of grade II or more immunological adverse events, secondaryOutcomes measure: Identification of a phenotypic "signature" of trogocytosis predictive of the occurrence of serious hematological side effects., secondaryOutcomes measure: Determination of the trogocytosis level of normal lymphocytes and NK cells in healthy subjects, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352216, orgStudyIdInfo id: Elo-Ger-2023-1642, briefTitle: Prevalence of Synovitis in Patients With Haemophilia A, acronym: SynoPrev, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-02, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University Hospital, Bonn, class: OTHER, collaborators name: Swedish Orphan Biovitrum, descriptionModule briefSummary: The aim of this study is to evaluate the prevalence of synovitis in adult patients with haemophilia A., conditionsModule conditions: Haemophilia A, conditions: Synovitis, conditions: Hemophilia Arthropathy, conditions: Sonography, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS), outcomesModule primaryOutcomes measure: Haemophilia early arthropathy detection with ultrasound (HEAD-US), secondaryOutcomes measure: The Hemophilia Joint Health Score version 2.1 (HJHS), secondaryOutcomes measure: PROMIS-29 Questionaire, secondaryOutcomes measure: Haemophilia Activities List (HAL), otherOutcomes measure: Baseline Characteristics, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Bonn, status: RECRUITING, city: Bonn, state: NRW, zip: 53113, country: Germany, contacts name: Andreas C. Strauss, PD Dr. med., role: CONTACT, phone: 004922828714176, email: andreas.strauss@ukbonn.de, contacts name: Andreas C. Strauss, PD Dr. med., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 50.73438, lon: 7.09549, hasResults: False
protocolSection identificationModule nctId: NCT06352203, orgStudyIdInfo id: AUT/23.02, briefTitle: Effect of Probiotics on the Intestinal Microbiota of Pediatric Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-11, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: ProbiSearch SL, class: INDUSTRY, descriptionModule briefSummary: Numerous studies have described an altered gut microbiota composition (dysbiosis) in patients with neurodevelopmental disorders that can be correlated with their symptoms, especially gastrointestinal symptoms.An interventional, randomised, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic supplement on the microbiota composition of children aged 3-7 years with neurodevelopmental issues.The duration of the study will be of 6 months approximately, including 6 months of product intake.Participants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group., conditionsModule conditions: Neurodevelopmental Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Probiotic, interventions name: Placebo, outcomesModule primaryOutcomes measure: Number of children with intestinal dysbiosis after 6 months of treatment., eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 7 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352190, orgStudyIdInfo id: SY-5007-I-04, briefTitle: A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Shouyao Holdings (Beijing) Co. LTD, class: OTHER, descriptionModule briefSummary: This is a single-center, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled SY-5007 administered orally., conditionsModule conditions: Healthy Subjects, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: [14C] SY-5007, outcomesModule primaryOutcomes measure: Total radioactivity in plasma PK: Cmax, primaryOutcomes measure: Total radioactivity in plasma PK: Tmax, primaryOutcomes measure: Total radioactivity in plasma PK: AUC0-t, primaryOutcomes measure: Total radioactivity in plasma PK: t½, primaryOutcomes measure: Total radioactivity in plasma PK: CL/F, primaryOutcomes measure: Whole blood to plasma total radioactivity ratio, primaryOutcomes measure: Cumulative total radioactivity in urine and faeces, primaryOutcomes measure: Metabolic profiling in plasma, urinary and fecal excretion, secondaryOutcomes measure: Cmax of SY-5007 and its metabolites, secondaryOutcomes measure: Tmax of SY-5007 and its metabolites, secondaryOutcomes measure: AUC0-t of SY-5007 and its metabolites, secondaryOutcomes measure: t½ of SY-5007 and its metabolites, secondaryOutcomes measure: CL/F of SY-5007 and its metabolites, secondaryOutcomes measure: Incidence of adverse events, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Beijing Friendship Hospital, Capital Medical University, city: Beijing, zip: 100050, country: China, contacts name: Ruihua Dong, MD, role: CONTACT, phone: 86-010-63139033, email: ruihua_dong_rw@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06352164, orgStudyIdInfo id: ZYS2024-03, briefTitle: Efficacy Classification Prediction of the Effects of Acupuncture on Abdominal Pain in Patients With Crohn's Disease, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-03-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Shanghai Institute of Acupuncture, Moxibustion and Meridian, class: OTHER, descriptionModule briefSummary: Machine learning algorithms are applied to discover gut flora markers that predict the clinical efficacy of acupuncture, so as to screen the appropriate population for acupuncture and optimise the allocation of healthcare resources., conditionsModule conditions: Crohn Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 55, type: ACTUAL, armsInterventionsModule interventions name: Acupuncture treatment, outcomesModule primaryOutcomes measure: Characterisation of gut microflora strains predictive of acupuncture efficacy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Institute of Acupuncture, Moxibustion and Meridian, city: Shanghai, zip: 200000, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06352151, orgStudyIdInfo id: 2022-041, briefTitle: Effects of Orofacial Therapy and Therapeutic Yoga in Children With Down Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-09-28, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Hasan Kalyoncu University, class: OTHER, descriptionModule briefSummary: The study aims to compare the effects of orofacial therapy and therapeutic yoga on swallowing, sleep habits, and quality of life in children with Down syndrome., conditionsModule conditions: Down Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Routine Physiotherapy Group, interventions name: Orofacial Treatment Group, interventions name: Therapeutic Yoga Group, outcomesModule primaryOutcomes measure: The Pediatric Functional Independence Measure, primaryOutcomes measure: Pediatric Eating Assessment Tool-10, primaryOutcomes measure: Children's Sleep Habits Questionnaire, primaryOutcomes measure: The Health-Related Quality of Life Scale-KIDSCREEN-27, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Hasan Kalyoncu University, status: RECRUITING, city: Gaziantep, zip: 27410, country: Turkey, contacts name: Aysenur Tuncer, PhD, role: CONTACT, phone: +903422118080, contacts name: Yasemin Kotevoglu, MSc, role: CONTACT, geoPoint lat: 37.05944, lon: 37.3825, hasResults: False
protocolSection identificationModule nctId: NCT06352138, orgStudyIdInfo id: ENCASE, briefTitle: Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients, acronym: ENCASE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Megalabs, class: INDUSTRY, collaborators name: Azidus Laboratories, descriptionModule briefSummary: Phase III, multicentre, double-blind, randomised, parallel, equivalence clinical trial to determine the efficacy, safety and immunogenicity of Megalabs® recombinant human alfa epoetin for subcutaneous use, compared to Eprex® (Janssen-Cilag Farmacêutica Ltda.), in the treatment of anaemia in participants with chronic renal disease, dependent on haemodialysis, conditionsModule conditions: Anemia of Chronic Kidney Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: multicentre, double-blind, randomised, parallel, equivalence trial, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 280, type: ESTIMATED, armsInterventionsModule interventions name: Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration., interventions name: Active comparator: European Union licenced epoetin alfa, outcomesModule primaryOutcomes measure: Mean Absolute Change in Hemoglobin Levels, primaryOutcomes measure: Change in Mean Hb Level, secondaryOutcomes measure: immunogenicity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Megalabs, city: Colonia Nicolich, state: Canelones, zip: 15000, country: Uruguay, contacts name: Victoria Rodriguez, MD, role: CONTACT, phone: 26836300, phoneExt: 3110, email: vrodriguez@megalabs.global, geoPoint lat: -34.81516, lon: -56.02435, hasResults: False
protocolSection identificationModule nctId: NCT06352125, orgStudyIdInfo id: TP-CLN-100503, briefTitle: An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-12-09, primaryCompletionDateStruct date: 2023-01-31, completionDateStruct date: 2023-01-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Haemonetics Corporation, class: INDUSTRY, collaborators name: ClinStatDevice, collaborators name: Boston Healthcare Technologies Consultants, LLC, descriptionModule briefSummary: This clinical trial is designed to assess the agreement of the TEG® 6s system using the Citrated K, KH, RTH, FFH, cartridge (hereafter referred to as the Heparin Neutralization (HN) Cartridge) with its comparators., conditionsModule conditions: Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 338, type: ACTUAL, armsInterventionsModule interventions name: TEG 6s Citrated K, KH, RTH, FFH Cartridge, interventions name: Clauss Fibrinogen, outcomesModule primaryOutcomes measure: Primary Method Comparison, primaryOutcomes measure: Primary Method Comparison, primaryOutcomes measure: Primary Method Comparison, primaryOutcomes measure: Primary Method Comparison, primaryOutcomes measure: Primary Method Comparison, primaryOutcomes measure: Primary Method Comparison, primaryOutcomes measure: Primary Method Comparison, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California - San Francisco, city: San Francisco, state: California, zip: 94143, country: United States, geoPoint lat: 37.77493, lon: -122.41942, locations facility: University of Colorado, city: Aurora, state: Colorado, zip: 80045, country: United States, geoPoint lat: 39.72943, lon: -104.83192, locations facility: Ochsner Clinic, city: New Orleans, state: Louisiana, zip: 70121, country: United States, geoPoint lat: 29.95465, lon: -90.07507, locations facility: Lifebridge Health (Sinai Hospital), city: Baltimore, state: Maryland, zip: 21215, country: United States, geoPoint lat: 39.29038, lon: -76.61219, locations facility: Massachusetts General Hospital, city: Boston, state: Massachusetts, zip: 02114, country: United States, geoPoint lat: 42.35843, lon: -71.05977, locations facility: University of Pittsburgh Medical Center, city: Pittsburgh, state: Pennsylvania, zip: 15213, country: United States, geoPoint lat: 40.44062, lon: -79.99589, locations facility: University of Texas Health Science Center - San Antonio, city: San Antonio, state: Texas, zip: 78229, country: United States, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06352112, orgStudyIdInfo id: 02.04.2024 - POP, briefTitle: Effects of the Hypopressive Exercises in Women With Pelvic Organ Prolapse, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-15, primaryCompletionDateStruct date: 2024-01-15, completionDateStruct date: 2024-02-15, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Hacettepe University, class: OTHER, collaborators name: Istanbul Training and Research Hospital, descriptionModule briefSummary: The aim of this study was compare home-based pelvic floor muscle training (PFMT) alone and home-based PFMT combined with hypopressive exercise (HE) in terms of pelvic floor muscle (PFM) activation and severity of pelvic floor dysfunction (PFD) in women with pelvic organ prolapse (POP) for eight weeks. For this purpose, the participants were randomly divided into two groups: \[PFMT alone (n:15) and PFMT combined with HE(n:17)\]. DuoBravo EMG device for evaluation of PFM activation and "Pelvic Floor Distress Inventory-20" was used to evaluate the severity of PFD. All evaluations were performed twice in total, at baseline and at week 8., conditionsModule conditions: Pelvic Floor Disorders, conditions: Prolapse; Female, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: Pelvic Floor Muscle Training, interventions name: Hypopressive Exercises, outcomesModule primaryOutcomes measure: Pelvic Floor Muscle Activation, secondaryOutcomes measure: Severity of pelvic floor dysfunction, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Istanbul Research and Training Hospital, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06352086, orgStudyIdInfo id: STUDY00009227, briefTitle: Understanding Visual Processing After Occipital Stroke, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2028-09, completionDateStruct date: 2029-09, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: University of Rochester, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate how visual orientation discrimination and metacognition (i.e., perceptual confidence) are affected by occipital stroke that causes hemianopia and quadrantanopia in adults. This research will provide insight as to how the residual visual system, which not directly damaged by the occipital stroke, processes orientation (assayed in terms of orientation discrimination) and metacognition (by measuring perceptual confidence for orientation discrimination). These measures will be used to refine computational models that attempt to explain how the brain copes with loss of primary visual cortex (V1) as a result of stroke. This knowledge is essential to devise more effective visual rehabilitation therapies for patients suffering from occipital strokes., conditionsModule conditions: Vision Loss Partial, conditions: Vision; Loss, Both Eyes, conditions: Hemianopia, Homonymous, conditions: Hemianopia, conditions: Quadrantanopia, conditions: Stroke, Ischemic, conditions: Stroke - Occipital Infarction, conditions: Cortical Blindness, conditions: Occipital Lobe Infarct, conditions: Peripheral Visual Field Defect of Both Eyes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 20, type: ESTIMATED, outcomesModule primaryOutcomes measure: Orientation discrimination threshold, primaryOutcomes measure: Perceptual Confidence in Orientation Discrimination, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False